FindTrial
Sign In

Efficacy of an Aqueous Suspension of Metal-Based Bismuth Nanoparticles in the Radiotherapy of Lacrimal Gland Adenoid Cystic Carcinoma

Efficacy of an Aqueous Suspension of Metal-Based Bismuth Nanoparticles in the Radiotherapy of Lacrimal Gland Adenoid Cystic Carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500115263
Enrollment
Unknown
Registered
2025-12-24
Start date
2025-12-30
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lacrimal Gland Adenoid Cystic Carcinoma

Interventions

Lacrimal Gland Adenoid Cystic Carcinoma:None

Sponsors

Beijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age between 18 and 60 years old (inclusive), gender not limited; 2. Patients diagnosed with adenoid cystic carcinoma of the lacrimal gland by pathological histology; 3. Patients with a history of good health and no history of inflammation or other diseases; 4. Patients with complete clinical medical records.

Exclusion criteria

Exclusion criteria: 1. Those diagnosed with other types of lacrimal gland tumors, or those with a history of other malignant tumors; 2. Those with heart, kidney, or liver dysfunction; 3. Those with other immune system diseases.

Design outcomes

Primary

MeasureTime frame
PDX model establishment success rate;—

Secondary

MeasureTime frame
Histological similarity;—

Countries

China

Contacts

Public ContactQiuzi Zhong

Beijing Hospital

drzhongqiuzi@163.com+86 10 8513 8522

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026